"We have spent over a decade working on manufacturing technologies to achieve cost efficiencies and scalability," said Dr. Marnix Bosch, Chief Technology Officer of NWBT. "NWBT has already achieved significant cost efficiencies by pioneering a unique batch manufacturing process. These efficiencies will be further enhanced by the automated system we have developed, and it is very gratifying to receive the allowance of this important US patent on our automated device."
The batch manufacturing process that NWBT has pioneered produces several years (typically at least 3 years) of personalized DCVax® vaccine for a patient in a single manufacturing run. The large, multi-year batch of the patient's vaccine is then frozen in single-dose vials and stored in standard bio freezers, making DCVax® an "off-the-shelf" product for that patient throughout the multi-year treatment period (and avoiding very costly repeat-cycles of manufacturing). The batch manufacturing process takes only 10 days. The shelf life and potency of the frozen DCVax® product have been validated.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis. The Company has two broad platform technologies: dendritic cell-based vaccines and therapeutic antibodies. The Company is focusing on development of its dendritic cell vaccines. The Company's lead clinical trial is a 240 patient double blind, randomized, placebo controlled Phase II trial in GBM. The Company has also received clearance from the FDA for a 600+ patient Phase III trial in prostate cancer, a
|SOURCE Northwest Biotherapeutics, Inc.|
Copyright©2009 PR Newswire.
All rights reserved